Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode

被引：37

作者：

Angell, Richard M. ^{[1
]}

Bamborough, Paul ^{[1
]}

Cleasby, Anne ^{[1
]}

Cockerill, Stuart G. ^{[1
]}

Jones, Katherine L. ^{[1
]}

Mooney, Christopher J. ^{[1
]}

Somers, Donald O. ^{[1
]}

Walker, Ann L. ^{[1
]}

机构：

[1] GlaxoSmithKline R&D, Med Res Ctr, Stevenage SG1 2NY, Herts, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 01期

关键词：

D O I：

10.1016/j.bmcl.2007.10.076

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The biphenyl amides (BPAs) are a novel series of p38 MAP kinase inhibitors. The discovery of the series through structure-based focused screening is described, and the binding mode of the compound is explained with reference to X-ray crystal structures. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：318 / 323

页数：6

共 23 条

[1] Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR [J].

Angell, Richard M. ;

Angell, Tony D. ;

Bamborough, Paul ;

Brown, David ;

Brown, Murray ;

Buckton, Jacky B. ;

Cockerill, Stuart G. ;

Edwards, Chris D. ;

Jones, Katherine L. ;

Longstaff, Tim ;

Smee, Penny A. ;

Smith, Kathryn J. ;

Somers, Don O. ;

Walker, Ann L. ;

Willson, Malcolm .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (01) :324-328

[2] N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck:: Indazoles as phenol isosteres with improved pharmacokinetics [J].

Bamborough, Paul ;

Angell, Richard M. ;

Bhamra, Inder ;

Brown, David ;

Bull, James ;

Christopher, John A. ;

Cooper, Anthony W. J. ;

Fazal, Lynsey H. ;

Giordano, Ilaria ;

Hind, Lucy ;

Patel, Vipulkumar K. ;

Ranshaw, Lisa E. ;

Sims, Martin J. ;

Skone, Philip A. ;

Smith, Kathryn J. ;

Vickerstaff, Emma ;

Washington, Melanie .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (15) :4363-4368

[3] Conversion of SB 203580-insensitive MBP kinase family members to drug-sensitive forms by a single amino-acid substitution [J].

Eyers, PA ;

Craxton, M ;

Morrice, N ;

Cohen, P ;

Goedert, M .

CHEMISTRY & BIOLOGY, 1998, 5 (06) :321-328

[4] Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity [J].

Fitzgerald, CE ;

Patel, SB ;

Becker, JW ;

Cameron, PM ;

Zaller, D ;

Pikounis, VB ;

O'Keefe, SJ ;

Scapin, G .

NATURE STRUCTURAL BIOLOGY, 2003, 10 (09) :764-769

[5]

Golas JM, 2003, CANCER RES, V63, P375

[6] Pathway to the clinic: Inhibition of p38 MAP kinase. A review of ten chemotypes selected for development [J].

Goldstein, DM ;

Gabriel, T .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (10) :1017-1029

[7] Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors [J].

Hennequin, LF ;

Thomas, AP ;

Johnstone, C ;

Stokes, ESE ;

Plé, PA ;

Lohmann, JJM ;

Ogilvie, DJ ;

Dukes, M ;

Wedge, SR ;

Curwen, JO ;

Kendrew, J ;

Lambert-van der Brempt, C .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (26) :5369-5389

[8] Small molecule p38 inhibitors: Novel structural features and advances from 2002-2005 [J].

Hynes, J ;

Leftheris, K .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (10) :967-985

[9]

Kamens J S, 2001, Curr Opin Investig Drugs, V2, P1213

[10] p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases [J].

Kumar, S ;

Boehm, J ;

Lee, JC .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) :717-726

← 1 2 3 →